drugset / Trial / NCT01627665
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
RandomizedCrossoverOpen-label
Summary
The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
Timeline
- Start
- 2011-10
- Primary completion
- 2014-06
- Completion
- 2014-06
Publications
- Foulon-Pinto G, Jourdi G, Perrin J, Abdoul J, Paris G, Gouin-Thibault I, Curis E, Lecompte T, Siguret V. Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months. Int J Lab Hematol. 2021 Aug;43(4):821-830. doi: 10.1111/ijlh.13443. Epub 2020 Dec 28.
- Marques P, Courand PY, Gouin-Thibault I, Zhygalina V, Bergerot D, Salem JE, Funck-Brentano C, Loriot MA, Azizi M, Blanchard A. P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. J Hypertens. 2019 Nov;37(11):2225-2231. doi: 10.1097/HJH.0000000000002150.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dabigatran etexilate | Unknown | 300 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 40 mg | — |
| Comparator | Clarithromycin | Small molecule | 1 g | — |
Indications
No indication recorded.